We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
(Approval lapsed) DUPIXENT dupilumab 200mg/1.14mL solution for injection in pre-filled syringe with needle shield (USA)
Section 19A approved medicine
(Approval lapsed) DUPIXENT dupilumab 200mg/1.14mL solution for injection in pre-filled syringe with needle shield (USA)
Section 19A approval holder
Sanofi - Aventis Australia Pty Ltd ABN 31 008 558 807
Phone
1800 818 806
Approved until
Status
Expired
Medicines in short supply/unavailable
DUPIXENT dupilumab 200 mg (175 mg/mL) solution for injection pre-filled syringe with needle shield - ARTG 302463
Indication(s)
Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.
Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.
Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment.
Images
